Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1822 1
1844 1
1879 1
1947 1
1948 1
1951 1
1952 1
1954 4
1958 1
1961 1
1962 1
1963 5
1964 5
1965 1
1966 1
1967 3
1968 3
1969 5
1970 6
1971 7
1972 2
1973 2
1974 2
1976 3
1977 1
1978 3
1979 1
1980 3
1981 5
1982 4
1983 4
1984 6
1985 3
1986 4
1987 4
1988 6
1989 6
1990 4
1991 2
1992 5
1994 2
1995 4
1996 3
1997 2
1998 2
1999 2
2000 3
2001 3
2002 1
2003 3
2004 4
2005 2
2006 5
2007 10
2008 10
2009 14
2010 13
2011 10
2012 35
2013 22
2014 21
2015 14
2016 11
2017 9
2018 7
2019 16
2020 11
2021 10
2022 14
2023 18
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Results by year

Filters applied: . Clear all
Page 1
Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides.
Monian P, Shivalila C, Lu G, Shimizu M, Boulay D, Bussow K, Byrne M, Bezigian A, Chatterjee A, Chew D, Desai J, Favaloro F, Godfrey J, Hoss A, Iwamoto N, Kawamoto T, Kumarasamy J, Lamattina A, Lindsey A, Liu F, Looby R, Marappan S, Metterville J, Murphy R, Rossi J, Pu T, Bhattarai B, Standley S, Tripathi S, Yang H, Yin Y, Yu H, Zhou C, Apponi LH, Kandasamy P, Vargeese C. Monian P, et al. Among authors: godfrey j. Nat Biotechnol. 2022 Jul;40(7):1093-1102. doi: 10.1038/s41587-022-01225-1. Epub 2022 Mar 7. Nat Biotechnol. 2022. PMID: 35256816
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma.
Riscal R, Bull CJ, Mesaros C, Finan JM, Carens M, Ho ES, Xu JP, Godfrey J, Brennan P, Johansson M, Purdue MP, Chanock SJ, Mariosa D, Timpson NJ, Vincent EE, Keith B, Blair IA, Skuli N, Simon MC. Riscal R, et al. Among authors: godfrey j. Cancer Discov. 2021 Dec 1;11(12):3106-3125. doi: 10.1158/2159-8290.CD-21-0211. Cancer Discov. 2021. PMID: 34244212 Free PMC article.
Stand up for your patients.
Godfrey J. Godfrey J. Br J Nurs. 2023 Apr 6;32(7):S3. doi: 10.12968/bjon.2023.32.7.S3. Br J Nurs. 2023. PMID: 37027408 No abstract available.
Pediatric Metacarpal Fractures.
Godfrey J, Cornwall R. Godfrey J, et al. Instr Course Lect. 2017 Feb 15;66:437-445. Instr Course Lect. 2017. PMID: 28594520
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Major A, et al. Among authors: godfrey j. Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. Blood Adv. 2023. PMID: 37026796 Free PMC article.
An update in treating transformed lymphoma.
Godfrey J, Leukam MJ, Smith SM. Godfrey J, et al. Best Pract Res Clin Haematol. 2018 Sep;31(3):251-261. doi: 10.1016/j.beha.2018.07.008. Epub 2018 Jul 25. Best Pract Res Clin Haematol. 2018. PMID: 30213394 Review.
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Zain J, Rosen S, Forman S, Popplewell L, Kwak L, Herrera AF. Mei M, et al. Among authors: godfrey j. Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485. Blood. 2023. PMID: 37339586
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Ong SY, Pak S, Mei M, Wang Y, Popplewell L, Baird JH, Herrera AF, Shouse G, Nikolaenko L, Zain J, Godfrey J, Htut M, Aribi A, Spielberger R, Mansour J, Forman SJ, Palmer J, Budde LE. Ong SY, et al. Among authors: godfrey j. Am J Hematol. 2023 Nov;98(11):1751-1761. doi: 10.1002/ajh.27069. Epub 2023 Sep 5. Am J Hematol. 2023. PMID: 37668287
391 results